US 12,478,601 B2
Dietary product devoid of at least two non essential amino acids
Oliver D. K. Maddocks, Glasgow (GB); and Karen Vousden, Glasgow (GB)
Assigned to Cancer Research Technology Limited, London (GB)
Filed by CANCER RESEARCH TECHNOLOGY LIMITED, London (GB)
Filed on Feb. 27, 2023, as Appl. No. 18/174,706.
Application 18/174,706 is a continuation of application No. 15/999,666, granted, now 12,042,477, previously published as PCT/GB2017/050458, filed on Feb. 22, 2017.
Claims priority of application No. 1603098 (GB), filed on Feb. 23, 2016; and application No. 1609441 (GB), filed on May 27, 2016.
Prior Publication US 2023/0277492 A1, Sep. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4709 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 31/198 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61P 17/00 (2006.01); A61P 17/04 (2006.01); A61P 17/10 (2006.01); A61P 31/04 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/198 (2013.01) [A61K 9/0056 (2013.01); A61K 9/0095 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 22 Claims
 
1. A method of treating a cancer in a subject in need thereof, the method comprising administering to the subject:
(a) a therapeutically effective amount of a dietary product,
wherein the dietary product comprises a plurality of amino acids or salts thereof, wherein the plurality of amino acids or salts thereof comprises methionine or a salt thereof, leucine or a salt thereof, phenylalanine or a salt thereof, isoleucine or a salt thereof, valine or a salt thereof, lysine or a salt thereof, threonine or a salt thereof, histidine or a salt thereof, and tryptophan or a salt thereof,
wherein the dietary product is substantially a sole source of exogenous amino acids consumed by the subject, and
wherein the dietary product is devoid of glycine, serine, and proline, and salts, prodrugs, homodimers, heterodimers, and esters of glycine, serine and proline; and
(b) a therapeutically effective amount of one or more therapeutic agents; wherein the cancer consumes exogenous serine and is characterized by phosphoglycerate dehydrogenase (PHGDH) expression reduced relative to non-cancerous tissue, wherein the cancer is colorectal cancer, pancreatic cancer, intestinal cancer, lymphoma, or breast cancer.